Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
12/31/2024 | 09/30/2024 | ||||
---|---|---|---|---|---|
Revenue | -67.65% | 161.54% | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -67.65% | 161.54% | |||
Cost of Revenue | -- | -- | |||
Gross Profit | -67.65% | 161.54% | |||
SG&A Expenses | 23.39% | -3.97% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -96.85% | 25.20% | |||
Total Operating Expenses | 22.19% | -1.94% | |||
Operating Income | -22.25% | 1.99% | |||
Income Before Tax | -330.51% | 2.68% | |||
Income Tax Expenses | -- | -- | |||
Earnings from Continuing Operations | -330.51% | 2.68% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | -330.51% | 2.68% | |||
EBIT | -22.25% | 1.99% | |||
EBITDA | -23.77% | 1.72% | |||
EPS Basic | -294.25% | 3.07% | |||
Normalized Basic EPS | -15.85% | 0.18% | |||
EPS Diluted | -294.25% | 3.07% | |||
Normalized Diluted EPS | -15.85% | 0.18% | |||
Average Basic Shares Outstanding | 9.22% | 0.36% | |||
Average Diluted Shares Outstanding | 9.22% | 0.36% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |